



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/711,709	11/13/2000	Moshe Kushnir	287985/002	7668

7590 07/24/2003

Dekel Patent Ltd Attn Mr David Klein
Beit Harofim
18 Menuha Ve Nahala Street
Suite 27
Rehovot, 76209
ISRAEL

[REDACTED] EXAMINER

GEORGE, KONATA M

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1616

DATE MAILED: 07/24/2003

13

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Applicant No.	Applicant(s)
	09/711,709	KUSHNIR ET AL.
	Examiner Konata M. George	Art Unit 1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 03 June 2003.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 11,13,23 and 25 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 13 and 25 is/are rejected.
- 7) Claim(s) 11 and 23 is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 13 November 2000 is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claims 11, 13, 23 and 25 are pending in this application.

Action Summary

1. In view of the newly cited art the final rejection is being withdrawn and prosecution continued.
2. Examiner acknowledges the cancellation of claims 10, 12, 22 and 24.
3. The rejection of claims 11, 13, 22 and 24 under 35 U.S.C. 102(b) over Nakoneczny et al. is hereby withdrawn.
4. The rejection of claims 11 and 23 under 35 U.S.C. 103(a) over Nakoneczny et al. is hereby withdrawn.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claim 25 is rejected under 35 U.S.C. 102(b) as being anticipated by D'Angelo et al. (US 5,405,614).

D'Angelo teaches an electronic transdermal delivery system. The device comprises a collapsible container for containing the drug, the container having a drug release opening, a displaceable member in engagement with the container for expelling

Art Unit: 1616

the drug from the container via the release opening, etc. (col. 2, lines 14-30). Column 3, lines 58-66 teach an additional feature the invention may contain which is a flow control means in the conduit means for controlling the flow of drugs to the skin area, the flow control means including a flow control valve. Column 3, lines 7-16 teach that the drug should be biphasic and virtually all hydrochloride selections of therapeutic drugs meet this requirement.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over D'Angelo et al. (US 5,405,614).

D'Angelo teaches an electronic transdermal delivery system. The device comprises a collapsible container for containing the drug, the container having a drug release opening, a displaceable member in engagement with the container for expelling the drug from the container via the release opening, etc. (col. 2, lines 14-30). Column 3, lines 58-66 teach an additional feature the invention may contain which is a flow control means in the conduit means for controlling the flow of drugs to the skin area, the flow control means including a flow control valve. Column 3, lines 7-16 teach that the drug should be biphasic and virtually all hydrochloride selections of therapeutic drugs meet

this requirement. D'Angelo does not teach the apparatus used to treat Parkinson's disease.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate any drug that treats Parkinson's disease as column 3, lines 7-16 describe the type of drugs that can be used in the invention which are virtually all hydrochloride selections of therapeutic drugs.

Allowable Subject Matter

7. Claims 11 and 23 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is (703) 308-4646. The examiner can normally be reached from 8AM to 5:30PM Monday to Thursday, and on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page, can be reached at (703) 308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and for After Final communications.

Art Unit: 1616

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.



Konata M. George
Patent Examiner
Art Unit 1616